Johnson & Johnson (JNJ) Position Raised by Dubuque Bank & Trust Co.
Dubuque Bank & Trust Co. increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.3% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 122,348 shares of the company’s stock after purchasing an additional 419 shares during the quarter. Johnson & Johnson accounts for approximately 2.6% of Dubuque Bank & Trust Co.’s investment portfolio, making the stock its 6th largest holding. Dubuque Bank & Trust Co.’s holdings in Johnson & Johnson were worth $16,905,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in the stock. Dowling & Yahnke LLC lifted its holdings in Johnson & Johnson by 15.2% in the third quarter. Dowling & Yahnke LLC now owns 88,870 shares of the company’s stock valued at $12,279,000 after acquiring an additional 11,715 shares during the period. Chatham Capital Group Inc. lifted its holdings in Johnson & Johnson by 0.8% in the third quarter. Chatham Capital Group Inc. now owns 58,383 shares of the company’s stock valued at $8,067,000 after acquiring an additional 469 shares during the period. Ramsay Stattman Vela & Price Inc. lifted its holdings in Johnson & Johnson by 1.0% in the third quarter. Ramsay Stattman Vela & Price Inc. now owns 70,313 shares of the company’s stock valued at $9,715,000 after acquiring an additional 665 shares during the period. Oregon Public Employees Retirement Fund lifted its holdings in Johnson & Johnson by 0.7% in the third quarter. Oregon Public Employees Retirement Fund now owns 640,260 shares of the company’s stock valued at $88,465,000 after acquiring an additional 4,458 shares during the period. Finally, Stoneridge Investment Partners LLC lifted its holdings in Johnson & Johnson by 67.8% in the third quarter. Stoneridge Investment Partners LLC now owns 13,186 shares of the company’s stock valued at $1,822,000 after acquiring an additional 5,326 shares during the period. 66.20% of the stock is owned by hedge funds and other institutional investors.
Shares of JNJ stock opened at $132.40 on Monday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.72 and a quick ratio of 1.40. The company has a market cap of $355.22 billion, a PE ratio of 16.19, a price-to-earnings-growth ratio of 2.11 and a beta of 0.68. Johnson & Johnson has a 1-year low of $118.62 and a 1-year high of $148.99.
Johnson & Johnson announced that its Board of Directors has approved a stock buyback program on Monday, December 17th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the company to purchase up to 1.5% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its shares are undervalued.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 12th. Stockholders of record on Tuesday, February 26th will be paid a dividend of $0.90 per share. This represents a $3.60 annualized dividend and a dividend yield of 2.72%. The ex-dividend date is Monday, February 25th. Johnson & Johnson’s payout ratio is 44.01%.
In other Johnson & Johnson news, Director Charles Prince bought 2,000 shares of Johnson & Johnson stock in a transaction dated Friday, December 14th. The stock was acquired at an average cost of $134.37 per share, with a total value of $268,740.00. Following the purchase, the director now directly owns 28,520 shares in the company, valued at approximately $3,832,232.40. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, CAO Ronald A. Kapusta sold 3,643 shares of the company’s stock in a transaction that occurred on Thursday, December 13th. The stock was sold at an average price of $147.31, for a total value of $536,650.33. Following the transaction, the chief accounting officer now directly owns 13,641 shares of the company’s stock, valued at $2,009,455.71. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 465,746 shares of company stock valued at $67,951,916. Corporate insiders own 0.22% of the company’s stock.
A number of research analysts have issued reports on JNJ shares. Citigroup decreased their price target on Johnson & Johnson from $148.00 to $139.00 and set a “neutral” rating for the company in a report on Wednesday, January 2nd. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $165.00 price target for the company in a report on Tuesday, November 20th. Morgan Stanley set a $140.00 price target on Johnson & Johnson and gave the company a “hold” rating in a report on Thursday, December 20th. Wells Fargo & Co reissued an “outperform” rating and issued a $160.00 price target (up from $155.00) on shares of Johnson & Johnson in a report on Wednesday, October 17th. Finally, Credit Suisse Group boosted their price target on Johnson & Johnson from $149.00 to $152.00 and gave the company an “outperform” rating in a report on Wednesday, October 17th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have assigned a buy rating to the stock. Johnson & Johnson presently has an average rating of “Hold” and an average target price of $142.20.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: Understanding Average Daily Trade Volume
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.